Health Care

Advicenne S.A. pioneers rare‑renal treatments: discover Sibnayal’s breakthrough efficacy, plus anxiety‑relief Likozam and seizure‑control Levidcen, driving patient outcomes and growth.

Moderna’s $1.5B credit line and first revenue rise in three years signal a strategic turnaround from its pandemic‑era focus to a diversified, mRNA‑driven growth trajectory.

TEYI Pharmaceutical soars amid China’s anti‑flu rally, hitting a 3‑day limit‑up on 27 Nov as ILI cases surge, boosting investor confidence in antiviral stocks.

Tenaya Therapeutics is pioneering heart‑disease cures, targeting root causes to transform cardiovascular care despite current financial volatility.

BioNTech’s takeover of CureVac moves forward—over 99% shareholder support, $1.25 bn valuation, and a December 3 deadline. Find out how this merger could reshape Europe’s biotech scene.

GSK PLC sees analyst upgrades and expanding market forecasts, including asthma spacers, prefilled syringes, and Ebola vaccine growth, boosting investor confidence.

Body and Mind Inc. blends medical and recreational cannabis to tap Canada’s booming 15%‑CAGR market—investors should track its clinical milestones, regulatory approvals, and Vancouver‑based supply chain edge for next‑phase growth.

Emergent BioSolutions surges to an 80‑plus Relative Strength rating, beating peers and positioning itself to capture the booming Ebola vaccine market with a solid PE of 8.07 and $584 m cap. Click to see how its tech momentum and pipeline could drive…

Explore why Doximity’s recent price dip and a strong buy rating signal a smart entry for investors eyeing rapid telehealth growth and secure medical collaboration.

Ocugen, Inc. drives regenerative medicine for cartilage and joint health, offering innovative therapies amid biotech volatility—discover its clinical progress and investment potential.